Skip to main content
. Author manuscript; available in PMC: 2011 Oct 19.
Published in final edited form as: Circulation. 2010 Oct 4;122(16):1612–1620. doi: 10.1161/CIRCULATIONAHA.109.923482

Table 2.

Baseline patient cardiac intervention history and drug regimens.

EECP (N=28) SHAM (N=14) P
Prior CABG 19 (76%) 11 (79%) .481
Prior PTCA 23 (92%) 12 (88%) .776
Prior Myocardial Infarction 17 (61%) 6 (43%) .284
Multivessil CAD 25 (89%) 13 (93%) .718
Diabetes 21 (84%) 11 (79%) .804
Hypertension 23 (92%) 12 (88%) .776
Hyperlipidemia 26 (93%) 14 (100%) .317
Lipid Lowering 28 (100%) 14 (100%) .999
Beta-Blocker 24 (86%) 11 (79%) .569
Calcium Channel Blocker 11 (39%) 6 (43%) .829
Long Lasting NItrates 25 (89%) 12 (88%) .744
ACE Inhibition (or)ARB 26 (93%) 12 (88%) .469
Insulin 9 (32%) 5 (36%) .822

There were no significant differences (p>0.05) in baseline characteristics, drug regimens, and cardiac intervention history between SHAM and EECP group at baseline. Values are presented as the number of patients per group and the percentage within each group.